Adults 40 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Effect of Green Tea (GT) and Black Tea (BT) Consumption on Percentage of Cells With Positive Staining for Apoptosis, Proliferation, Oxidation, and Inflammation in Malignant Radical Prostatectomy Tissue Compared to Water Control Using Immunohistochemistry.Primary· 6 weeks
To determine the effect of Green Tea and Black Tea consumption on Prostate cancer tissue by examining programmed cell death, cell proliferation, cell oxidation, and cellular inflammation in that malignant radical prostatectomy tissue compared to water control using immunohistochemistry.
Staining proliferation (Ki67)
Group
Value
95% CI
Arm I - Green Tea
2.48
± 1.83
Arm II - Water
2.3
± 1.55
Arm III - Decaffeinated Black Tea
4.38
± 4.1
Staining apoptosis Tunel
Group
Value
95% CI
Arm I - Green Tea
6.96
± 8.56
Arm II - Water
6.7
± 9.1
Arm III - Decaffeinated Black Tea
6.57
± 8.85
Staining oxidative DNA Damage 8OHdG
Group
Value
95% CI
Arm I - Green Tea
5.5
± 7.4
Arm II - Water
7.27
± 10.68
Arm III - Decaffeinated Black Tea
11.23
± 12.01
Staining Proliferation Bax
Group
Value
95% CI
Arm I - Green Tea
37.4
± 11
Arm II - Water
37.06
± 8.71
Arm III - Decaffeinated Black Tea
37.35
± 7.58
Staining Proliferation Bcl-2
Group
Value
95% CI
Arm I - Green Tea
2.92
± 2.97
Arm II - Water
5.21
± 6.91
Arm III - Decaffeinated Black Tea
6.48
± 6.25
NFKB cytoplasmic staining
Group
Value
95% CI
Arm I - Green Tea
21.23
± 20.46
Arm II - Water
22.3
± 14.62
Arm III - Decaffeinated Black Tea
19.21
± 14.63
NFkB nuclear staining
Group
Value
95% CI
Arm I - Green Tea
1.46
± 1.79
Arm II - Water
5.13
± 6.37
Arm III - Decaffeinated Black Tea
4.58
± 6.61
Concentration of Tea Polyphenols, Their Metabolites, and Colonic Metabolites in Prostate TissueSecondary· 6 weeks
Examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and serum prostate-specific antigen (PSA) levels.
EGCG
Group
Value
95% CI
Arm I - Green Tea
42.1
± 32.4
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
0
± 0
ECG
Group
Value
95% CI
Arm I - Green Tea
17.8
± 10.1
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
0
± 0
4" MeEGCG
Group
Value
95% CI
Arm I - Green Tea
38.9
± 19.5
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
0
± 0
Theaflavin
Group
Value
95% CI
Arm I - Green Tea
0
± 0
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
0
± 0
Concentration of Tea Polyphenols and Methyl-metabolites in Urine After the Consumption of Green Tea (GT) and Black Tea (BT).Secondary· 6 weeks
Concentration of tea polyphenols and methyl-metabolites in urine after the consumption of GT and BT. No polyphenols were found after water consumption
EGC
Group
Value
95% CI
Arm I - Green Tea
9.2
± 16
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
.4
± .4
EC
Group
Value
95% CI
Arm I - Green Tea
4.8
± 6.1
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
.3
± .3
4'-MeEGC
Group
Value
95% CI
Arm I - Green Tea
8.0
± 18
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
.2
± .3
Theaflavins
Group
Value
95% CI
Arm I - Green Tea
0
± 0
Arm II - Water
0
± 0
Arm III - Decaffeinated Black Tea
0
± 0
Prostate Specific Antigen (PSA) After the Consumption of Green Tea (GT) and Black Tea (BT).Secondary· 6 weeks
Group
Value
95% CI
Arm I - Green Tea
8.4
± 4.3
Arm II - Water
10.0
± 9.0
Arm III - Decaffeinated Black Tea
9.6
± 6.0
Sponsor's own description
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
PURPOSE: This randomized phase II trial is studying green tea to see how well it works compared with black tea and water in treating patients with prostate cancer undergoing surgery.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05681325 — Evaluation of Antioxidant and Anti-inflammatory Effect of Matcha Tea Intake on Periodontal Health
· NA
· unknown
NCT04160559 — Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
· NA
· withdrawn
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
· recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
· Phase 2
· recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
· Phase 2
· recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris
· Phase 2
· recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate
· Phase 2, PHASE3
· recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio
· Phase 3
· not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer,
· not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi
· Phase 2
· not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 31 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00685516.